Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis : results from an Italian multicenter study
OBJECTIVES: The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and predictive factors influencing the patients' treatment persistence.
MATERIAL AND METHODS: This study included adult patients affected by moderate-to-severe AD treated with dupilumab for at least 16 weeks who visited 7 dermatologic outpatient clinics in Lazio, Italy, from January 2019 until August 2021.
RESULTS: A total of 659 adult patients (345 male [52.3%], mean age: 42.8 years) with an average treatment duration of 23.3 months were enrolled in the study. Overall, 88.6% and 76.1% of patients were still on treatment after 12 and 24 months, respectively. The drug survival rate for discontinuation due to AEs and dupilumab ineffectiveness was 95.0% at 12 months and 90.0% at 24 months. The main reasons for drug discontinuation included inefficacy (29.6%), failed compliance (17.4%), persistent efficacy (20.4%) and adverse events (7.8%). Adult AD onset (≥18 years) and EASI score severity measured at the last follow-up visit were the only factors significantly associated with lower drug survival.
CONCLUSION: This study revealed an increased cumulative probability of dupilumab survival at 2 years, reflected by a sustained effectiveness and a favorable safety profile of the drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
The Journal of dermatological treatment - 34(2023), 1 vom: 29. Dez., Seite 2230685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gori, Niccolò [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
420K487FSG |
|---|
| Anmerkungen: |
Date Completed 05.07.2023 Date Revised 05.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/09546634.2023.2230685 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359021751 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359021751 | ||
| 003 | DE-627 | ||
| 005 | 20231226075957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09546634.2023.2230685 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359021751 | ||
| 035 | |a (NLM)37400981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gori, Niccolò |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis |b results from an Italian multicenter study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.07.2023 | ||
| 500 | |a Date Revised 05.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and predictive factors influencing the patients' treatment persistence | ||
| 520 | |a MATERIAL AND METHODS: This study included adult patients affected by moderate-to-severe AD treated with dupilumab for at least 16 weeks who visited 7 dermatologic outpatient clinics in Lazio, Italy, from January 2019 until August 2021 | ||
| 520 | |a RESULTS: A total of 659 adult patients (345 male [52.3%], mean age: 42.8 years) with an average treatment duration of 23.3 months were enrolled in the study. Overall, 88.6% and 76.1% of patients were still on treatment after 12 and 24 months, respectively. The drug survival rate for discontinuation due to AEs and dupilumab ineffectiveness was 95.0% at 12 months and 90.0% at 24 months. The main reasons for drug discontinuation included inefficacy (29.6%), failed compliance (17.4%), persistent efficacy (20.4%) and adverse events (7.8%). Adult AD onset (≥18 years) and EASI score severity measured at the last follow-up visit were the only factors significantly associated with lower drug survival | ||
| 520 | |a CONCLUSION: This study revealed an increased cumulative probability of dupilumab survival at 2 years, reflected by a sustained effectiveness and a favorable safety profile of the drug | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atopic dermatitis | |
| 650 | 4 | |a drug survival | |
| 650 | 4 | |a dupilumab | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Sernicola, Alvise |e verfasserin |4 aut | |
| 700 | 1 | |a Tolino, Ersilia |e verfasserin |4 aut | |
| 700 | 1 | |a Mariano, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Galluzzo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Moretta, Gaia |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a D'Alessio, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Sansone, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Maffei, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Paolino, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrao, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Cascia, Lauro |e verfasserin |4 aut | |
| 700 | 1 | |a Addio, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Di Nardo, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Chiricozzi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Del Duca, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Cristaudo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Pallotta, Sabatino |e verfasserin |4 aut | |
| 700 | 1 | |a Panasiti, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Pellacani, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Potenza, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, Ketty |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatological treatment |d 1992 |g 34(2023), 1 vom: 29. Dez., Seite 2230685 |w (DE-627)NLM088851680 |x 1471-1753 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:1 |g day:29 |g month:12 |g pages:2230685 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09546634.2023.2230685 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 1 |b 29 |c 12 |h 2230685 | ||